Assay for the detection and quantification of HBV cccDNA by real-time PCR
The persistence of covalently closed circular (ccc) DNA of Hepatitis B Virus (HBV) in liver cells is believed to be the major reason for relapse after completion of HBV antiviral therapy. Up to now, there is no sensitive method to quantify cccDNA in infected liver cells. A set of primers were designed to specifically amplify DNA fragments from HBV cccDNA but not from viral genomic DNA. A good linear range was obtained when 100 to 10<7 >copies of HBV cccDNA were used as template in the quantitative real-time PCR. Not only is this method rapid, economical, highly sensitive, it can be used to monitor HBV cccDNA in infected human liver biopsies and to guide patients undergoing long-term anti-HBV therapy.
Patent Number: US20040058314A1
Application Number: US2003449801A
Inventor: He, Ming Liang | Kung, Hsiang Fu | Lin, Marie, Chia Mi
Priority Date: 29 May 2002
Priority Number: US20040058314A1
Application Date: 29 May 2003
Publication Date: 25 Mar 2004
IPC Current: C12Q000170
US Class: 435005 | 4350912
Title: Assay for the detection and quantification of HBV cccDNA by real-time PCR
Usefulness: Assay for the detection and quantification of HBV cccDNA by real-time PCR
Summary: M1 is useful for detecting cccDNA of HBV in the form of a HBV cccDNA genome from the infected liver cell and for providing guidance to the patient undergoing long term anti-HBV therapy.
Novelty: Specific detection of Hepatitis B virus (HBV) covalently closed circular (ccc) DNA from liver cell biopsies by real-time PCR, useful for guiding long-term anti-HBV therapy
生物医学
病原
香港
